Sept 3 (Reuters) - Regeneron Pharmaceuticals Inc said a mid-stage study of its experimental treatment for gout, Arcalyst, met the main goal and reduced the incidence of gout flares by 81 percent.
Sept 3 (Reuters) - Regeneron Pharmaceuticals Inc said a mid-stage study of its experimental treatment for gout, Arcalyst, met the main goal and reduced the incidence of gout flares by 81 percent.
